NCT04157985 2025-12-11Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid TumorsUniversity of PittsburghPhase 3 Completed161 enrolled
NCT06052852 2025-11-17Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesBolt Biotherapeutics, Inc.Phase 1 Terminated17 enrolled
NCT05259696 2025-08-20GLIMMER-01Palleon Pharmaceuticals, Inc.Phase 1/2 Completed69 enrolled 13 charts
NCT04291105 2025-03-26Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsVyriad, Inc.Phase 2 Recruiting87 enrolled
NCT05429866 2023-03-08Immunological Variables Associated to ICI Toxicity in Cancer PatientsJules Bordet InstitutePhase 2 Unknown441 enrolled